MVA-BN
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Monkeypox (Mpox)
Conditions
Monkeypox (Mpox)
Trial Timeline
Oct 21, 2024 → May 7, 2026
NCT ID
NCT06549530About MVA-BN
MVA-BN is a phase 2 stage product being developed by Bavarian Nordic for Monkeypox (Mpox). The current trial status is active. This product is registered under clinical trial identifier NCT06549530. Target conditions include Monkeypox (Mpox).
What happened to similar drugs?
0 of 2 similar drugs in Monkeypox (Mpox) were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06549530 | Phase 2 | Active |
| NCT00189943 | Phase 1 | Completed |
Competing Products
5 competing products in Monkeypox (Mpox)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 1/2 | 33 |
| BNT166a | BioNTech | Phase 2 | 39 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 44 |
| JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) | Bavarian Nordic | Phase 3 | 41 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 39 |